Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common blood pressure drug protect PTSD Patients' hearts?

NCT ID NCT02560805

Knowledge-focused Sponsor: Emory University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to understand why people with post-traumatic stress disorder (PTSD) have a higher risk of heart disease and high blood pressure. Researchers will measure nerve activity and test whether the drug losartan can lower high adrenaline levels during stress. The study includes 134 veterans aged 18-65 with and without PTSD.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
losartan
What this could lead to
If successful, this study could point toward a way to lower heart disease risk in people with PTSD by targeting nerve activity.
What could go wrong
This is an early-phase study with only 134 participants, so results may not apply to everyone. The main goal is to understand mechanisms, not to prove a treatment works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 134 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2015

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * veterans ages 18-65 years old with PTSD and without PTSD (controls) matched for age, gender, and race. Exclusion Criteria: * pregnancy * hypertension * diabetes * heart or vascular disease * illicit drug use * excessive alcohol use (\>2 drinks per day) * hyperlipidemia * autonomic dysfunction * current treatment with clonidine, beta blockers, angiotensin-converting-enzyme (ACE) inhibitors, or angiotensin II receptor blockers (ARBs) * treatment with monoamine oxidase (MAO) inhibitors within the last 14 days * any serious systemic disease * chronic kidney disease defined as estimated glomerular filtration rate (GFR) \< 60 cc/min * hyperkalemia (serum potassium \> 5 meq/dL) * systolic blood pressure \< 100 mm Hg * diastolic blood pressure \< 60 mm Hg * heart rate \< 50 beats/min * known hypersensitivity to ARBs or beta blockers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stress disorders, post-traumatic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

post-traumatic stress disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stress disorders, post-traumatic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Atlanta VA Medical Center

    RECRUITING

    Decatur, Georgia, 30033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.